| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2565032 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2012 | 7 Pages |
Abstract
⺠The chronic use of benzodiazepines may decrease cognitive function in schizophrenia. ⺠Daytime benzodiazepines can be gradually tapered without significant adverse effects. ⺠A reduction of 25-50% of the daily dose per 2-4 weeks may be a safe tapering strategy. ⺠Reduction or cessation of benzodiazepine use can improve verbal and working memory. ⺠Tapering of benzodiazepines can improve subjective QOL and psychiatric symptoms.
Keywords
DIEPSSEPSSGAsQOLPANSSFGAsDSM-IV-TRCGI-SQuality of lifeSchizophreniastandard deviationBenzodiazepinesanalysis of varianceANOVADiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text RevisionExtrapyramidal symptomsCognitive functionpositive and negative syndrome scaleFirst-generation antipsychoticsSecond-generation antipsychotics
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Rei Kitajima, Seiya Miyamoto, Tomomi Tenjin, Kazuaki Ojima, Shin Ogino, Nobumi Miyake, Keisuke Fujiwara, Yasuyuki Funamoto, Jun Arai, Sachiko Tsukahara, Yukie Ito, Masanori Tadokoro, Kiriko Anai, Yasuhiro Kaneda, Noboru Yamaguchi,